Variational AI signs Merck drug discovery deal worth up to $349 million

Image: Primary

Published Tuesday, November 3, 2026 · 12:11 AM EST

Variational AI announced a collaboration with Merck to design and optimize small molecule drug candidates against two undisclosed targets. The agreement gives Merck exclusive rights to develop and commercialize compounds arising from the work. Variational AI will receive an upfront payment and is eligible for milestones, with a total potential deal value of up to USD$349 million. It will use a version of its Enki platform fine-tuned on Merck's proprietary data to generate and optimize candidates for Merck's designated targets. The stated deal value includes conditional milestone payments.

Sources

BioSpace

Published by Tech & Business, a media brand covering technology and business. This story was sourced from BioSpace and reviewed by the T&B editorial agent team.

Back to Newswire

Keep reading

Full wire

AI Products

Nvidia reportedly requires cloud clients to direct 51%+ of services outside China

Nvidia verbally told cloud computing clients to sell 51%+ of their services to non-Chinese companies, the Financial Times reported, citing sources.

Security

Attackers target unpatched WordPress payment flaw that exposes wallet credentials

Attackers are attempting to exploit an unpatched vulnerability in the CryptoPayment Gateway WordPress plugin, Defused Cyber said. CVE-2026-81648 has a CVSS score of 10.0 and affects versions 1.2.1 through 1.2.2, the latest version.

Robotics

Tesla tests two dozen Cybercabs on Detroit-area roads

Tesla is testing two dozen Cybercabs from its Southfield facility on roads in the Detroit area, The Detroit News reported.

AI Science

Preprint reports agent context compression with up to 50.68% fewer attention pairs

Researchers report a method that matched or exceeded an uncompressed language-model agent's accuracy on long-running tasks while using up to 50.68% fewer end-to-end attention pairs, a measure of attention computation.

AI Capital

Trajectory raises $45 million and opens model post-training platform

Trajectory has raised $45 million in Series A funding at a $300 million valuation and is making its model post-training platform publicly available, TechCrunch reported. Sequoia led the round, with participation from Nvidia, Bessemer Venture Partners and Bain Capital Ventures.

Robotics AI

Tutor raises $75M Series B led by a16z

Tutor raised a $75M Series B led by a16z, bringing its total funding to $117M, Forbes reported. The company builds AI warehouse robots and is training a foundation model for robotics, putting the financing alongside its work on both robots and their underlying AI.